Sanofi SA

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

24 Feb 2024 09:51:53 By Nasdaq GlobeNewswire

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23 Feb 2024 12:45:30 By Nasdaq GlobeNewswire

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

23 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

22 Feb 2024 13:02:45 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - January 2024

20 Feb 2024 17:40:58 By Nasdaq GlobeNewswire

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

16 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

15 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

05 Feb 2024 02:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

01 Feb 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

01 Feb 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

25 Jan 2024 14:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

23 Jan 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - December 2023

17 Jan 2024 16:57:07 By Nasdaq GlobeNewswire

Press Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

09 Jan 2024 01:30:00 By Nasdaq GlobeNewswire

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

21 Dec 2023 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - November 2023

18 Dec 2023 15:59:30 By Nasdaq GlobeNewswire

Press Release: Availability of the Q4 2023 Memorandum for modelling purposes

15 Dec 2023 01:30:00 By Nasdaq GlobeNewswire

Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

15 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

11 Dec 2023 16:08:15 By Nasdaq GlobeNewswire

Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

10 Dec 2023 19:31:03 By Nasdaq GlobeNewswire